Urogen Pharma Q4 Earnings Call Highlights

Urogen Pharma (NASDAQ:URGN) executives used the company’s fiscal 2025 earnings call to highlight early commercial momentum for newly launched Zusduri, continued growth from its established product ...

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb.

BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026

BeOne Medicines Q4 earnings and revenue beat the Street's expectations; the outlook missed by a small margin. Read why I have ...

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

Protara Therapeutics: TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in ...

Women with severe burn injuries are more likely than men to develop blood poisoning

The skin forms a natural barrier that prevents bacteria entering the body. Severe burns stop this protective function from ...
Fox 12 Oregon

Ezra Kaplan

Ezra Kaplan is an investigative reporter for Fox 12. He comes from Chicago but fell in love with the West and swears off shoveling snow. Though he has been a journalist for over a decade, Ezra spent ...